antidiabetici

Antidiabetici are medications used to treat diabetes mellitus by lowering blood glucose and reducing the risk of long-term complications. The term covers insulin preparations and a range of non-insulin agents that act through different mechanisms to correct hyperglycemia.

In type 1 diabetes, insulin therapy is essential to replace the body’s absent insulin. In type 2 diabetes, antidiabetic drugs are used to improve glycemic control as part of a stepwise strategy, often starting with metformin and progressing to add-ons or insulin if needed. Treatments are chosen based on patient factors such as age, comorbidity, kidney and liver function, and risk of hypoglycemia.

Common classes and their general actions include: insulin preparations (rapid-acting, short-acting, intermediate-acting, and long-acting analogs) to replace insulin; metformin, which reduces hepatic glucose production and improves insulin sensitivity; sulfonylureas and meglitinides that stimulate pancreatic insulin release; DPP-4 inhibitors and GLP-1 receptor agonists that enhance incretin effects to boost glucose-dependent insulin secretion; SGLT2 inhibitors that promote urinary glucose excretion; thiazolidinediones that increase insulin sensitivity; and alpha-glucosidase inhibitors that slow carbohydrate absorption in the gut. Combination regimens are common and may include oral agents with or without insulin.

Safety and monitoring considerations include the risk of hypoglycemia, especially with insulin and secretagogues, and variable effects on body weight. Other concerns involve kidney and liver function, risk of lactic acidosis with metformin in renal impairment, edema with thiazolidinediones, and infections with SGLT2 inhibitors. Regular monitoring of blood glucose, renal and hepatic function, and cardiovascular status is recommended.